anti-PD1 treatmentimmune checkpoint therapyTNG260pembrolizumab
…t CoREST inhibition by TNG260 sensitizes STK11-mutant tumors to anti-PD1 treatment. TNG260, in combination with pembrolizumab, is being evaluated …
7,227articles mentioning treatments
16,644treatment mentions
4,719distinct treatments extracted
0%of mentions human-reviewed
All extracted treatments
Showing 3,901–3,960 of 4,719, ordered by supporting articles. Choose a treatment to see its evidence.
multidrug antihypertensive therapy1multifidus stimulation1multifocal intraocular lens implantation1multimodal analgesia procedures1multimodal pain regimen1multimodal therapies1multimodal/palliative treatment1multimodality imaging1multispecific antibody treatments1multitargeted combination therapies1mumps vaccine1muscular rehabilitation1musculoskeletal pain interventions1musculoskeletal rehabilitation1myopia control treatments1nBCA1nail hardening preparations1naloxone1naloxone dosing1nasal decongestant sprays1nasal surgery1nasogastric tube1nasogastric tube feeding1nebuliser treatment1neoadjuvant SBRT1neoadjuvant and perioperative chemoimmunotherapy1neoadjuvant anti-PD-1-based therapy1neoadjuvant chemo-immunotherapy1neoadjuvant or palliative chemotherapy1neoadjuvant platinum-based chemotherapy1neoadjuvant systemic therapy1neoadjuvant/adjuvant therapy1neoantigen vaccines1nephron-sparing procedures1nerve transfers1neuraxial techniques1neuroendovascular treatments1neurointerventional techniques1neurointerventional therapy1neuromodulation techniques1neuromodulators1neuromonitoring1neuromuscular blockade1neurosurgical evacuation1neurosurgical interventions1neurosurgical resection1neurosurgical support1new therapies1new treatment1next-generation cancer treatments1nil per oral status1nitrate therapy1no treatment1nocturnal non-invasive ventilation1nocturnal polygraphy1non-anthracycline chemotherapy1non-iloprost treatment1non-indicated antihypertensive treatment1non-invasive approach1non-invasive positive pressure ventilation1
Articles mentioning treatments
7,227 articles · page 231 of 603lymphodepleting chemotherapyAGX-148oral head and neck squamous cell carcinomamelanomathyroid cancersolid tumorsProvidence Institutional Review BoardClinicalTrials.gov
…ard and experimental therapies. Patients undergo tumor harvest, lymphodepleting chemotherapy, adoptive transfer of AGX-148 and high-dose IL-2 for one week, …
immunotherapyNanO 2Glioblastoma MultiformeNanO2PaclitaxelTNBCTriple-negative breast cancerDOD GrantBALB/c mice
… experiments, we tested the effect of NanO2 in combination with immunotherapy (IT), chemotherapy (CTX, paclitaxel) or both IT and CTX. BALB/c…
Triplet therapyanthracycline chemotherapyFTY720Flt3LTNBCDoxil D1NCT05029999
…s) as well as by blocking lymphocyte egress with FTY720.Results Triplet therapy significantly delayed tumor progression and extended median sur…
immunotherapyBreast cancerQUICKARRAYS, Inc
…y mapped the TME to identify features potentially predictive of immunotherapy response. FFPE (Formalin-Fixed Paraffin-Embedded) tissue slide …
T-FUSUniversity of Virginiacancerbreast cancerBCNIH DP5OD031846αCD40
…t of CD4+ T cells following rechallenge (figure 2O).Conclusions T-FUS+αCD40 represents a novel paradigm for immunotherapy of BC-capab…
anti-PD-1 therapyPD-1 therapyMD Anderson Cancer CenterKAN-001non-small cell lung cancerNSCLCCRCHUMCanadian Council
… evaluated in the MCA205 murine tumor model in combination with anti-PD-1 therapy. Comparative arms included treatment with FMT from ICI-non-resp…
immune checkpoint blockadeHER2-targeted therapyLeica BiosystemsIndica Labsgastric and gastroesophageal junction (GEJ) adenocarcinomaHER2-amplified colorectal cancerHER2-low breast cancerHER2-positive breast cancer
…, suggesting possible synergy between HER2-targeted therapy and immune checkpoint blockade.In HER2-amplified colorectal cancer, PD-L1 expression and immun…
immunotherapychemotherapyMassachusetts General HospitalMGH Histopathology Research CoreTNBCImmunomedics/GileadSacituzumab govitecantriple-negative breast cancerhuman breast cancer
…ody drug conjugates to activate anti-tumor immunity and enhance immunotherapy response.Acknowledgements We gratefully acknowledge Immunomedic…
Adoptive CTL therapyimmunotherapymelanoma-specificExtramammary Paget’s disease (EMPD)IL-2EMPDmelanomaRadiother Oncolsolid tumorsEBV-related cancers+1 more
…es in solid tumors, yet limited data exist in the EMPD context. Adoptive CTL therapy, which involves the ex vivo expansion and activation of autolog…
ImmunotherapyAzaAzacytidineAMLAcute Myeloid Leukemia
… AML has remained largely unchanged over the last four decades. Immunotherapy is a promising therapy in many cancers including AML. T cell ex…
immunotherapyEwing SarcomaChildren’s Oncology GroupIL1RAP
…on of the immune environment in ES may reveal the blockades for immunotherapy efforts and potential new pathways to be exploited in the futur…